elacestrant
Selected indexed studies
- Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. (J Clin Oncol, 2022) [PMID:35584336]
- Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups. (Clin Cancer Res, 2024) [PMID:39087959]
- Elacestrant: First Approval. (Drugs, 2023) [PMID:37060385]
_Worker-drafted node — pending editorial review._
Connections
elacestrant is a side effect of
Sources
- Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. (2022) pubmed
- Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups. (2024) pubmed
- Elacestrant: First Approval. (2023) pubmed
- Elacestrant. (2012) pubmed
- Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer. (2024) pubmed
- Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. (2021) pubmed
- Elacestrant and the Promise of Oral SERDs. (2022) pubmed
- Elacestrant: a new FDA-approved SERD for the treatment of breast cancer. (2023) pubmed
- US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer. (2024) pubmed
- Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer. (2026) pubmed